West Pharmaceutical Services INC Form 4 insider transactions

Rodolphe Jean Poussot, SVP of Strategy & Corporate Development at West Pharmaceutical Services, reported the conversion of restricted stock units into common stock and a subsequent sale for tax obligations.

Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services Inc., reported the vesting of performance stock units and subsequent tax-related share disposition.

West Pharmaceutical Services VP, Chief Accounting Officer Chad Winters reported the vesting of performance stock units and subsequent tax-related share disposition.

WEST PHARMACEUTICAL SERVICES INC's President, CEO, and Board Chair, Eric Mark Green, reported the acquisition of common stock through PSU vesting and RSU conversion, alongside related tax-driven dispositions.

Annette F Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services, reported recent acquisitions and dispositions of company common stock and restricted stock units.

West Pharmaceutical Services' CFO, Robert W. McMahon, acquired common stock through RSU vesting and subsequently sold a portion for tax obligations.

West Pharmaceutical Services Director Janet Haugen reported the acquisition of phantom stock units and beneficial ownership of restricted stock units.

Norman D. Finch, Jr., SVP, GC & Corporate Secretary of West Pharmaceutical Services Inc., was granted 192 restricted stock units and 459 stock options.

West Pharmaceutical Services Director Janet Haugen reported an acquisition of phantom stock units, increasing her beneficial ownership.

West Pharmaceutical Services' CFO, Robert W. McMahon, was granted significant equity awards, including restricted stock units and stock options, on August 11, 2025.

Janet Haugen, a Director at West Pharmaceutical Services Inc., was awarded 58 phantom stock units on June 30, 2025, as part of her compensation package.

Shane Alden Campbell, SVP at West Pharmaceutical Services, reports acquisition of restricted stock units and stock options.

Director Douglas Michels reported the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.

Director Paolo Pucci reports the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.

Director Janet Brutschea Haugen reports changes in beneficial ownership of West Pharmaceutical Services Inc. common stock, including acquisition of restricted stock units and disposal of shares.

Robert Friel, a director at West Pharmaceutical Services, reported the acquisition of 1,071 restricted stock units on May 6, 2025.

Director Myla Lai Goldman acquired 1,071 shares of West Pharmaceutical Services Inc. restricted stock on May 6, 2025, which will vest at the next annual shareholder meeting.

Director Molly Joseph reports acquisition of 1,071 restricted stock units in West Pharmaceutical Services.

Thomas W. Hofmann, a director at West Pharmaceutical Services, acquired 1,071 shares of common stock on May 6, 2025.

Director Deborah Keller reports the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.

Director William F. Feehery acquired 1,071 shares of West Pharmaceutical Services common stock through restricted stock units, as reported in a recent SEC Form 4 filing.

Director Stephen H. Lockhart acquired 1,071 shares of restricted stock units in West Pharmaceutical Services, Inc.

Mark A. Buthman, a director at West Pharmaceutical Services, acquired 1,071 shares of common stock on May 6, 2025.

Director Janet Brutschea Haugen acquired phantom stock units in West Pharmaceutical Services, to be settled upon termination as a director.

Bernard Birkett, CFO of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.

Cindy Reiss-Clark, Chief Commercial Officer of West Pharmaceutical Services, reports the acquisition and disposal of company stock and stock options.

Kimberly Banks MacKay, SVP, GC & Corporate Secretary of West Pharmaceutical Services, reports acquisition and disposal of common stock and stock options on February 18, 2025.

Annette Favorite, a Senior VP & Chief HR Officer at West Pharmaceutical Services, reported the acquisition and disposal of company stock and stock options on February 18, 2025.

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.

Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services, reports acquisition and disposal of common stock and stock options.